Region:Global
Author(s):Shubham
Product Code:KRAD3482
Pages:96
Published On:November 2025
By Product & Services:The product and services segment includes consumables, instruments, and services. Consumables, such as reagents and kits, are essential for conducting genomic tests, while instruments include the machinery used for testing. Services encompass the analytical and diagnostic services provided by laboratories.
The consumables sub-segment is dominating the market due to the increasing volume of genomic tests being conducted globally. The demand for reagents and kits is driven by the rising number of diagnostic laboratories and hospitals adopting genomic testing for various applications, including oncology and rare diseases. Additionally, advancements in technology have led to the development of more efficient and cost-effective consumables, further boosting their market share. The services segment is projected to experience solid growth momentum in the coming years.
By Technology:The technology segment includes Next-Generation Sequencing (NGS), Microarray, Polymerase Chain Reaction (PCR), Sanger Sequencing, and Others. NGS is a high-throughput method that allows for rapid sequencing of large amounts of DNA, while PCR is a widely used technique for amplifying DNA sequences.
The Next-Generation Sequencing (NGS) sub-segment is leading the market due to its ability to provide comprehensive genomic data quickly and accurately. The growing adoption of NGS in clinical diagnostics, particularly in oncology and genetic testing, is a significant factor contributing to its dominance. Furthermore, the decreasing costs associated with NGS technology have made it more accessible to a broader range of healthcare providers, enhancing its market presence. Microarray technology is expanding at a notable pace, driven by technological developments that provide greater accuracy and high resolution for comprehensive analysis of gene expression and genetic variations.
The Global Precision Genomic Testing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Agilent Technologies, Inc., QIAGEN N.V., BGI Genomics, Myriad Genetics, Inc., Guardant Health, Inc., Foundation Medicine, Inc., Invitae Corporation, 23andMe, Inc., Fulgent Genetics, Inc., Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Natera, Inc. contribute to innovation, geographic expansion, and service delivery in this space.
The future of precision genomic testing is poised for significant transformation, driven by technological advancements and increasing healthcare investments. As telehealth services expand, more patients will gain access to genomic testing, enhancing early diagnosis and treatment options. Additionally, collaborations between genomic testing companies and biotech firms are expected to foster innovation, leading to the development of more cost-effective and efficient testing solutions that cater to diverse patient needs, ultimately reshaping the healthcare landscape.
| Segment | Sub-Segments |
|---|---|
| By Product & Services | Consumables Instruments Services |
| By Technology | Next-Generation Sequencing (NGS) Microarray Polymerase Chain Reaction (PCR) Sanger Sequencing Others |
| By Application | Oncology Rare Diseases Reproductive Health Cardiovascular Diseases Infectious Diseases Others |
| By End-User | Hospitals Diagnostic Laboratories Research Institutions Pharmaceutical Companies Academic Institutions Others |
| By Sample Type | Blood Samples Saliva Samples Tissue Samples Urine Samples Others |
| By Region | North America Europe Asia-Pacific Latin America Middle East & Africa |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Oncology Genomic Testing | 120 | Oncologists, Genetic Counselors |
| Rare Disease Testing | 90 | Pediatricians, Rare Disease Specialists |
| Prenatal Genetic Screening | 70 | Obstetricians, Maternal-Fetal Medicine Experts |
| Pharmacogenomics | 60 | Clinical Pharmacologists, Healthcare Providers |
| Consumer Genomic Testing | 80 | Direct-to-Consumer Genetic Testing Companies, Marketing Managers |
The Global Precision Genomic Testing Market is valued at approximately USD 15.55 billion, driven by advancements in genomic technologies, the increasing prevalence of genetic disorders, and the rising demand for personalized medicine.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.
